ITRM20030601A1 - Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. - Google Patents

Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.

Info

Publication number
ITRM20030601A1
ITRM20030601A1 IT000601A ITRM20030601A ITRM20030601A1 IT RM20030601 A1 ITRM20030601 A1 IT RM20030601A1 IT 000601 A IT000601 A IT 000601A IT RM20030601 A ITRM20030601 A IT RM20030601A IT RM20030601 A1 ITRM20030601 A1 IT RM20030601A1
Authority
IT
Italy
Prior art keywords
cdr
amino acid
acid sequence
antibodies
heavy chain
Prior art date
Application number
IT000601A
Other languages
English (en)
Italian (it)
Inventor
Simona Capsoni
Sonia Covaceuszach
Doriano Lamba
Original Assignee
Lay Line Genomics Spa
Sissa Scoula Int Superiore Studi Avanzati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lay Line Genomics Spa, Sissa Scoula Int Superiore Studi Avanzati filed Critical Lay Line Genomics Spa
Priority to IT000601A priority Critical patent/ITRM20030601A1/it
Priority to BRPI0418202-2A priority patent/BRPI0418202A/pt
Priority to ES09008366T priority patent/ES2377535T3/es
Priority to CN2004800405657A priority patent/CN1906212B/zh
Priority to HUE10003283A priority patent/HUE027475T2/en
Priority to ES10003283.8T priority patent/ES2559429T3/es
Priority to US10/583,618 priority patent/US8296079B2/en
Priority to DK09008366.8T priority patent/DK2138512T3/da
Priority to EP04806887A priority patent/EP1709076B1/en
Priority to DK04806887.8T priority patent/DK1709076T3/da
Priority to SI200431828T priority patent/SI2138512T1/sl
Priority to DK10003283.8T priority patent/DK2218737T3/en
Priority to EP10003283.8A priority patent/EP2218737B1/en
Priority to PL09008366T priority patent/PL2138512T3/pl
Priority to SI200432296T priority patent/SI2218737T1/sl
Priority to AU2004303633A priority patent/AU2004303633B2/en
Priority to PL10003283.8T priority patent/PL2218737T3/pl
Priority to CA 2688944 priority patent/CA2688944C/en
Priority to AT09008366T priority patent/ATE534665T1/de
Priority to PT100032838T priority patent/PT2218737E/pt
Priority to PT09008366T priority patent/PT2138512E/pt
Priority to EP09008366A priority patent/EP2138512B8/en
Priority to PCT/IT2004/000722 priority patent/WO2005061540A2/en
Priority to EP20100011513 priority patent/EP2308894A3/en
Priority to CA2551796A priority patent/CA2551796C/en
Priority to JP2006546489A priority patent/JP4652341B2/ja
Priority to CN200910260472.XA priority patent/CN101724070B/zh
Publication of ITRM20030601A1 publication Critical patent/ITRM20030601A1/it
Priority to IL176495A priority patent/IL176495A/en
Priority to ZA200605200A priority patent/ZA200605200B/xx
Priority to JP2009213454A priority patent/JP2009291211A/ja
Priority to AU2009245889A priority patent/AU2009245889B2/en
Priority to HK10106395.6A priority patent/HK1139697B/en
Priority to HK11101429.6A priority patent/HK1147268B/en
Priority to US12/833,778 priority patent/US20110105727A1/en
Priority to US12/837,996 priority patent/US8246956B2/en
Priority to US12/838,034 priority patent/US8257710B2/en
Priority to US12/838,062 priority patent/US8877491B2/en
Priority to JP2012015219A priority patent/JP2012126726A/ja
Priority to CY20121100188T priority patent/CY1112611T1/el
Priority to IL220128A priority patent/IL220128A0/en
Priority to AU2012261567A priority patent/AU2012261567B2/en
Priority to US14/215,761 priority patent/US20140316113A1/en
Priority to US14/532,631 priority patent/US20150218264A1/en
Priority to JP2015001407A priority patent/JP2015110601A/ja
Priority to CY20161100159T priority patent/CY1117303T1/el
Priority to AU2016269485A priority patent/AU2016269485A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Neurosurgery (AREA)
IT000601A 2003-12-24 2003-12-24 Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. ITRM20030601A1 (it)

Priority Applications (46)

Application Number Priority Date Filing Date Title
IT000601A ITRM20030601A1 (it) 2003-12-24 2003-12-24 Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
CA2551796A CA2551796C (en) 2003-12-24 2004-12-23 Method for the humanization of antibodies and humanized antibodies thereby obtained
EP20100011513 EP2308894A3 (en) 2003-12-24 2004-12-23 Humanized anti-NGF antibodies
CN2004800405657A CN1906212B (zh) 2003-12-24 2004-12-23 抗体人源化的方法以及由此获得的人源化抗体
HUE10003283A HUE027475T2 (en) 2003-12-24 2004-12-23 Humanized anti-NGF antibodies
ES10003283.8T ES2559429T3 (es) 2003-12-24 2004-12-23 Anticuerpos anti-NGF humanizados
US10/583,618 US8296079B2 (en) 2003-12-24 2004-12-23 Method for the humanization of antibodies and humanized antibodies thereby obtained
DK09008366.8T DK2138512T3 (da) 2003-12-24 2004-12-23 Humaniserede anti-NGF-antistoffer
EP04806887A EP1709076B1 (en) 2003-12-24 2004-12-23 Method for the humanization of antibodies and humanized antibodies thereby obtained
DK04806887.8T DK1709076T3 (da) 2003-12-24 2004-12-23 Fremgangsmåde til humanisering af antistoffer og humaniserede antistoffer opnået derved
SI200431828T SI2138512T1 (sl) 2003-12-24 2004-12-23 Humanizirana anti-NGF protitelesa
DK10003283.8T DK2218737T3 (en) 2003-12-24 2004-12-23 Humanized anti-NGF antibodies
EP10003283.8A EP2218737B1 (en) 2003-12-24 2004-12-23 Humanized anti-NGF antibodies
PL09008366T PL2138512T3 (pl) 2003-12-24 2004-12-23 Humanizowane przeciwciała anty-NGF
SI200432296T SI2218737T1 (sl) 2003-12-24 2004-12-23 Humanizirana anti-NGF protitelesa
AU2004303633A AU2004303633B2 (en) 2003-12-24 2004-12-23 Method for the humanization of antibodies and humanized antibodies thereby obtained
ES09008366T ES2377535T3 (es) 2003-12-24 2004-12-23 Anticuerpos anti-NGF humanizados
CA 2688944 CA2688944C (en) 2003-12-24 2004-12-23 Humanized anti-ngf antibodies
AT09008366T ATE534665T1 (de) 2003-12-24 2004-12-23 Humanisierte anti-ngf-antikörper
PT100032838T PT2218737E (pt) 2003-12-24 2004-12-23 Anticorpos anti-ngf humanizados
PT09008366T PT2138512E (pt) 2003-12-24 2004-12-23 Anticorpos anti-ngf humanizados
EP09008366A EP2138512B8 (en) 2003-12-24 2004-12-23 Humanized anti-NGF antibodies
PCT/IT2004/000722 WO2005061540A2 (en) 2003-12-24 2004-12-23 Method for the humanization of antibodies and humanized antibodies thereby obtained
BRPI0418202-2A BRPI0418202A (pt) 2003-12-24 2004-12-23 método para a humanização de anticorpos e anticorpos humanizados assim obtidos
PL10003283.8T PL2218737T3 (pl) 2003-12-24 2004-12-23 Humanizowane przeciwciała anty-NGF
JP2006546489A JP4652341B2 (ja) 2003-12-24 2004-12-23 抗体のヒト化の方法およびそれによって得られるヒト化抗体
CN200910260472.XA CN101724070B (zh) 2003-12-24 2004-12-23 人源化抗-ngf抗体
IL176495A IL176495A (en) 2003-12-24 2006-06-22 Method for humanization of the variable regions vl and vh - of animal antibodies and human antibodies Products of the method
ZA200605200A ZA200605200B (en) 2003-12-24 2006-06-23 Method for the humanization of antibodies and humanized antibodies thereby obtained
JP2009213454A JP2009291211A (ja) 2003-12-24 2009-09-15 ヒト化抗ｎｇｆ抗体
AU2009245889A AU2009245889B2 (en) 2003-12-24 2009-11-25 Method for the humanization of antibodies and humanized antibodies thereby obtained
HK10106395.6A HK1139697B (en) 2003-12-24 2010-06-30 Humanized anti-ngf antibodies
HK11101429.6A HK1147268B (en) 2003-12-24 2010-06-30 Humanized anti-ngf antibodies
US12/833,778 US20110105727A1 (en) 2003-12-24 2010-07-09 Method for the humanization of antibodies and humanized antibodies thereby obtained
US12/838,034 US8257710B2 (en) 2003-12-24 2010-07-16 Method for the treatment of pain with humanized anti-nerve growth factor antibodies
US12/838,062 US8877491B2 (en) 2003-12-24 2010-07-16 Polynucleotides encoding humanized anti-NGF antibodies
US12/837,996 US8246956B2 (en) 2003-12-24 2010-07-16 Humanized anti-nerve growth factor antibodies
JP2012015219A JP2012126726A (ja) 2003-12-24 2012-01-27 ヒト化抗ｎｇｆ抗体
CY20121100188T CY1112611T1 (el) 2003-12-24 2012-02-23 Ανθρωποποιημενα αντισωματα αντι-ngf
IL220128A IL220128A0 (en) 2003-12-24 2012-06-03 Method for the humanization of antibodies and humanized antibodies thereby obtained
AU2012261567A AU2012261567B2 (en) 2003-12-24 2012-12-07 Method for the humanization of antibodies and humanized antibodies thereby obtained
US14/215,761 US20140316113A1 (en) 2003-12-24 2014-03-17 Method for the humanization of antibodies and humanized antibodies thereby obtained
US14/532,631 US20150218264A1 (en) 2003-12-24 2014-11-04 Methods for the humanization of antibodies and humanized antibodies thereby obtained
JP2015001407A JP2015110601A (ja) 2003-12-24 2015-01-07 ヒト化抗ｎｇｆ抗体
CY20161100159T CY1117303T1 (el) 2003-12-24 2016-02-26 Ανθρωποποιημενα αντισωματα anti-ngf
AU2016269485A AU2016269485A1 (en) 2003-12-24 2016-12-07 Method for the humanization of antibodies and humanized antibodies thereby obtained

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000601A ITRM20030601A1 (it) 2003-12-24 2003-12-24 Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.

Publications (1)

Publication Number Publication Date
ITRM20030601A1 true ITRM20030601A1 (it) 2005-06-25

Family

ID=34708536

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000601A ITRM20030601A1 (it) 2003-12-24 2003-12-24 Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.

Country Status (19)

Country Link
US (7) US8296079B2 (enExample)
EP (4) EP1709076B1 (enExample)
JP (4) JP4652341B2 (enExample)
CN (2) CN101724070B (enExample)
AT (1) ATE534665T1 (enExample)
AU (4) AU2004303633B2 (enExample)
BR (1) BRPI0418202A (enExample)
CA (2) CA2551796C (enExample)
CY (2) CY1112611T1 (enExample)
DK (3) DK2218737T3 (enExample)
ES (2) ES2559429T3 (enExample)
HU (1) HUE027475T2 (enExample)
IL (2) IL176495A (enExample)
IT (1) ITRM20030601A1 (enExample)
PL (2) PL2138512T3 (enExample)
PT (2) PT2218737E (enExample)
SI (2) SI2218737T1 (enExample)
WO (1) WO2005061540A2 (enExample)
ZA (1) ZA200605200B (enExample)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
CN101171034B (zh) 2005-03-03 2014-06-18 免疫医疗公司 人源化l243抗体
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
ITRM20050332A1 (it) * 2005-06-24 2006-12-25 Lay Line Genomics Spa Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore.
NZ569204A (en) * 2005-12-21 2012-03-30 Micromet Ag Pharmaceutical compositions with resistance to soluble CEA - comprising antibodies that bind to CD3 and CEA
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
PL2187964T3 (pl) 2007-08-10 2015-03-31 Regeneron Pharma Ludzkie przeciwciała o wysokim powinowactwie przeciw ludzkiemu czynnikowi wzrostu nerwu
EP2388323B1 (en) * 2008-01-11 2016-04-13 Gene Techno Science Co., Ltd. Humanized anti-9 integrin antibodies and the uses thereof
BRPI0905955A8 (pt) * 2008-02-04 2018-05-08 Lay Line Genomics Spa anticorpo ani trka, anticorpo ou derivado, derivado de um anticorpo, combinação de um anticorpo ou derivado, composição farmaceutica, método, polipetídeo, ácido nucléico codificante de um aniticorpo ou derivado do mesmo, vetor, sistema de expressão ,mamífero transgênico não humano e kit compreendo um anticorpo ou derivado
EP2282769A4 (en) 2008-04-29 2012-04-25 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
KR20110016959A (ko) 2008-06-03 2011-02-18 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
EP2297209A4 (en) 2008-06-03 2012-08-01 Abbott Lab IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
US8822645B2 (en) 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
RU2016116516A (ru) 2008-12-08 2018-12-07 Мандифарма Интернэшнл Корпорейшн Лимитед Композиции ингибиторов тирозинкиназных рецепторов белков
KR101711222B1 (ko) * 2008-12-18 2017-02-28 에라스무스 유니버시티 메디컬 센터 로테르담 인간화 항체들을 발현하는 비-인간 유전자이식 동물들 및 그의 이용
AU2010216152B2 (en) 2009-02-17 2015-05-14 Ucb Biopharma Sprl Antibody molecules having specificity for human OX40
ES2514319T3 (es) 2009-05-04 2014-10-28 Abbvie Research B.V. Anticuerpos contra el factor de crecimiento nervioso (NGF) con estabilidad in vivo mejorada
MX2011012047A (es) 2009-05-13 2011-12-14 Genzyme Corp Inmunoglobulinas humanas anti-cd52.
AR078651A1 (es) 2009-10-15 2011-11-23 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
KR20130031247A (ko) 2010-03-17 2013-03-28 애보트 리서치 비.브이. 항―신경 성장 인자（ｎｇｆ） 항체 조성물
KR20130100118A (ko) 2010-08-03 2013-09-09 아비에 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
ES2665954T3 (es) 2010-08-19 2018-04-30 Zoetis Belgium S.A. Anticuerpos anti-NGF y su uso
US9046513B2 (en) 2010-08-26 2015-06-02 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9783601B2 (en) 2010-12-01 2017-10-10 Alderbio Holdings Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
GB2528811A (en) * 2011-05-06 2016-02-03 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same
SG10201500957QA (en) * 2011-05-06 2015-04-29 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same
PT3498732T (pt) * 2011-05-06 2022-02-02 Zoetis Services Llc Anticorpos anti-fator de crescimento do nervo e método para preparação e utilização dos mesmos
GB2504889C (en) * 2011-05-06 2015-08-26 Nvip Pty Ltd Therapeutic canine immunoglobulins and methods of using the same
GB201114858D0 (en) * 2011-08-29 2011-10-12 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of using the same
US9580496B2 (en) 2011-05-06 2017-02-28 Nexvet Australia Pty Ltd Therapeutic canine immunoglobulins and methods of using same
CA2835094C (en) * 2011-05-06 2020-12-22 David Gearing Anti-nerve growth factor antibodies and methods of preparing and using the same
AU2012252152B2 (en) * 2011-05-06 2016-07-07 Zoetis Services Llc Anti-nerve growth factor antibodies and methods of preparing and using the same
US9102673B2 (en) 2011-07-12 2015-08-11 Merck Sharp & Dohme Corp. Substituted pyrrolo[3,2-c]pyridines as TrkA kinase inhibitors
RS56876B1 (sr) 2011-08-11 2018-04-30 Astellas Pharma Inc Novo antitelo protiv humanog ngf
US8926978B2 (en) 2011-10-25 2015-01-06 Anaptysbio, Inc. Antibodies directed against nerve growth factor (NGF)
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
AR089529A1 (es) 2011-12-30 2014-08-27 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
WO2013176970A1 (en) 2012-05-22 2013-11-28 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
UA113879C2 (xx) * 2012-06-08 2017-03-27 ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ
US20150183885A1 (en) * 2012-06-08 2015-07-02 Glenmark Pharmaceuticals S.A. Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof
EP2674439B1 (en) 2012-06-13 2017-02-01 Rottapharm Biotech S.r.l. Anti-TrkA antibodies, derivatives and uses thereof
PE20151179A1 (es) 2012-11-01 2015-09-12 Abbvie Inc Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas
US9127055B2 (en) 2013-02-08 2015-09-08 Astellas Pharma Inc. Method of treating pain with anti-human NGF antibody
AU2014227732A1 (en) 2013-03-15 2015-09-17 Abbvie Inc. Dual specific binding proteins directed against IL-1 beta and IL-17
AR095199A1 (es) * 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
WO2015039334A1 (en) 2013-09-22 2015-03-26 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
WO2015039333A1 (en) 2013-09-22 2015-03-26 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
CN103965357B (zh) 2013-12-31 2016-08-17 嘉和生物药业有限公司 一种抗人rankl抗体
WO2015106290A1 (en) 2014-01-13 2015-07-16 Valerion Therapeutics, Llc Internalizing moieties
CN109820853B (zh) 2014-02-05 2022-05-10 Vm肿瘤药物有限责任公司 取代的杂环化合物在制备治疗癌症药物中的用途
WO2015143652A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2015143653A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2015143654A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
MA41097A (fr) * 2014-12-05 2017-10-10 Glenmark Pharmaceuticals Sa Anticorps anti-trka à propriétés inhibitrices améliorées et dérivés desdits anticorps destinés à être utilisés pour traiter les douleurs osseuses
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
EP3085709B1 (en) 2014-12-28 2019-08-21 Genor Biopharma Co., Ltd Humanized anti-human rankl antibody, pharmaceutical composition and use thereof
EP3247692B1 (en) 2015-01-23 2022-09-07 GVK Biosciences Private Limited Inhibitors of trka kinase
WO2016161572A1 (en) 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
WO2016190263A1 (ja) * 2015-05-22 2016-12-01 アステラス製薬株式会社 新規抗ヒトＮＧＦ抗体Ｆａｂフラグメント
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
US11680110B2 (en) 2017-07-31 2023-06-20 Hoffmann-La Roche Inc. Three-dimensional structure-based humanization method
US12391746B2 (en) 2018-02-20 2025-08-19 Emory University HPV proteins, antibodies, and uses in managing abnormal epithelial cell growth
AR114110A1 (es) 2018-02-28 2020-07-22 Lilly Co Eli Anticuerpo anti-trka
BR112020017701A2 (pt) 2018-03-12 2020-12-29 Zoetis Services Llc Anticorpos anti-ngf e métodos dos mesmos
WO2020068557A1 (en) * 2018-09-25 2020-04-02 BioLegend, Inc. Anti-tlr9 agents and compositions and methods for making and using the same
KR20220066002A (ko) 2019-03-20 2022-05-23 킨드레드 바이오사이언시스, 인코포레이티드 의학적 용도의 ngf 길항제
KR102265434B1 (ko) * 2019-08-20 2021-06-15 주식회사 케어젠 피부 미백 활성을 갖는 펩타이드 및 이의 용도
TW202124442A (zh) * 2019-09-13 2021-07-01 大陸商北京軒義醫藥科技有限公司 人源化抗ｃｌｄｎ１８．２抗體、編碼其的核酸分子、其產生方法、包含其的組合物、試劑盒及其用途
CN117186219B (zh) * 2020-04-17 2024-07-12 珠海泰诺麦博制药股份有限公司 抗人神经生长因子的抗体
CN116003590A (zh) 2020-08-06 2023-04-25 熙源安健医药（上海）有限公司 抗ngf抗体及其抗原结合片段、其制备方法和应用
AU2021382828A1 (en) * 2020-11-20 2022-10-06 Sunshine Lake Pharma Co., Ltd. Humanized anti-TrkA antibodies and uses thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4230691A (en) 1978-05-23 1980-10-28 The Massachusetts General Hospital Nerve growth factor antibody and process
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
SE465573B (sv) 1989-03-14 1991-09-30 Lope Medicine Ab Nervtillvaextfaktorpeptider, motsvarande antikroppar och foerfarande foer bestaemning av nativ nervtillvaextfaktor
DE69027683T2 (de) 1989-12-01 1997-02-13 Pharming Bv Herstellung rekombinanter polypeptide durch rinder und transgene methoden
US5147294A (en) * 1990-10-01 1992-09-15 Trustees Of Boston University Therapeutic method for reducing chronic pain in a living subject
WO1992008483A1 (en) 1990-11-13 1992-05-29 The Children's Medical Center Corporation CONTROLLING β-AMYLOID RELATED NEURONAL DEGENERATION BY ANTAGONIZING NGF-EFFECTED NEURONAL ACTIVITY
CA2097309A1 (en) 1990-11-30 1992-05-31 Peter S. Distefano Immunoassay and monoclonal antibodies useful for detecting truncated nerve growth factor receptor
EP0590058B1 (en) * 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
SG49597A1 (en) * 1992-02-06 1998-06-15 Schering Corp Design cloning and expression of humanized monoclonal antibodies against human interleukin-5
EP0578515A3 (en) * 1992-05-26 1995-05-10 Bristol Myers Squibb Co Humanized monoclonal antibodies.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
GB9402331D0 (en) * 1994-02-07 1994-03-30 Univ Mcgill Nerve growth factor structural analogs and their uses
US5747060A (en) 1996-03-26 1998-05-05 Euro-Celtique, S.A. Prolonged local anesthesia with colchicine
DE19732928C2 (de) 1997-07-31 2000-05-18 Gruenenthal Gmbh Verwendung substituierter Imidazolidin-2,4-dion-Verbindungen als Schmerzmittel
US6652864B1 (en) 1998-12-21 2003-11-25 Asilomar Pharmaceuticals, Inc. Compounds for intracellular delivery of therapeutic moieties to nerve cells
IT1306704B1 (it) 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
AU783964B2 (en) 1999-08-06 2006-01-05 S.I.S.S.A. Scuola Internazionale Superiore Di Studi Avanzati Non-human transgenic animals for the study of neurodegenerative syndromes
WO2001052843A1 (en) * 2000-01-18 2001-07-26 Mcgill University β-TURN PEPTIDOMIMETIC CYCLIC COMPOUNDS
US6548062B2 (en) * 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
AU5081401A (en) * 2000-03-16 2001-10-03 Genentech Inc Anti-tissue factor antibodies with enhanced anticoagulant potency
FR2807660A1 (fr) 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
WO2002096356A2 (en) 2001-05-25 2002-12-05 Cornell Research Foundation, Inc. HIGH AFFINITY LIGAND FOR p75 NEUROTROPHIN RECEPTOR
KR20100132559A (ko) * 2001-05-30 2010-12-17 제넨테크, 인크. 다양한 질환의 치료에 유용한 항-엔지에프 항체
SE0102067D0 (sv) 2001-06-11 2001-06-11 A & Science Invest Ab Prevention of neovascularization of intervertebral discs and/or of tissues with local inflammation
ATE454137T1 (de) 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
JP2003231687A (ja) * 2002-02-04 2003-08-19 Japan Tobacco Inc ピラゾリル縮合環化合物及びその医薬用途
US6919426B2 (en) * 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
EP1545615A4 (en) 2002-10-04 2006-03-01 Rinat Neuroscience Corp METHODS OF TREATING CARDIAC ARRHYTHMIA AND PREVENTING DEATH OF CARDIAC ARRHYTHMIA USING NGF ANTAGONISTS
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
US7255860B2 (en) 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
WO2004032870A2 (en) 2002-10-08 2004-04-22 Rinat Neuroscience Corp. Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same
DK1891966T3 (da) 2002-12-20 2012-04-02 Lundbeck & Co As H Modulation af neurotrophinaktivitet; fremgangsmåde til screening
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
DK1575517T3 (da) 2002-12-24 2012-05-14 Rinat Neuroscience Corp Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme
US20040131515A1 (en) 2003-01-03 2004-07-08 Alexanian Ara J. Material heat treatment system and method statement regarding federally sponsored research or development
US20060147932A1 (en) 2003-01-18 2006-07-06 Alun Davies Methods of screening for modulators of nerve growth factor
KR20050111598A (ko) 2003-02-19 2005-11-25 리나트 뉴로사이언스 코퍼레이션 신경 성장 인자 길항제 및 ｎｓａｉｄ를 투여함으로써통증을 치료하는 방법 및 그것을 함유하는 조성물
UA97086C2 (uk) 2003-07-15 2012-01-10 Емджен, Інк. Виділене людське антитіло, яке специфічно зв'язується з фактором росту нервової тканини (ngf)
WO2005044293A2 (en) 2003-11-07 2005-05-19 Lay Line Genomics S.P.A. Compositions able to prevent neurodegenerative processes and methods of assaying the same
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
US7522822B2 (en) 2004-01-06 2009-04-21 Robert Trujillo Halogen lamp assembly with integrated heat sink
KR101637908B1 (ko) * 2004-04-07 2016-07-11 리나트 뉴로사이언스 코프. 신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법
ITRM20040212A1 (it) 2004-04-30 2004-07-30 Lay Line Genomics Spa Animale transgenico non umano come modello per malattie neurodegenerative e per la loro diagnosi precoce.
ME00226B (me) * 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
JP5096167B2 (ja) 2005-01-24 2012-12-12 メドイミューン リミテッド Ｎｇｆに対する特異的結合メンバー
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
ITRM20050332A1 (it) 2005-06-24 2006-12-25 Lay Line Genomics Spa Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore.
US7290968B1 (en) 2006-03-06 2007-11-06 Shih-Chang Wu Extension fixture for turning tool
EP2129401B8 (en) 2006-12-21 2020-01-15 Amgen Inc. Stable buffered formulations containing polypeptides
AU2008255352B2 (en) * 2007-05-31 2014-05-22 Genmab A/S Stable IgG4 antibodies
PL2187964T3 (pl) 2007-08-10 2015-03-31 Regeneron Pharma Ludzkie przeciwciała o wysokim powinowactwie przeciw ludzkiemu czynnikowi wzrostu nerwu
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
JP5737944B2 (ja) 2007-12-17 2015-06-17 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 間質性膀胱炎の治療
EP2141593A1 (en) 2008-07-02 2010-01-06 Telefonaktiebolaget L M Ericsson (Publ) Requirement dependent allocation of hardware units to applications
US20120294913A1 (en) 2010-02-03 2012-11-22 Morinage Milk Industry Co., Ltd Method for manufacturing aloe powder
KR20130031247A (ko) 2010-03-17 2013-03-28 애보트 리서치 비.브이. 항―신경 성장 인자（ｎｇｆ） 항체 조성물

Also Published As

Publication number Publication date
CA2688944A1 (en) 2005-07-07
DK2218737T3 (en) 2016-02-29
WO2005061540A3 (en) 2005-09-22
IL176495A0 (en) 2006-10-05
US20150218264A1 (en) 2015-08-06
PT2218737E (pt) 2016-03-18
ES2377535T3 (es) 2012-03-28
CY1117303T1 (el) 2017-04-26
WO2005061540A2 (en) 2005-07-07
EP2308894A2 (en) 2011-04-13
CA2551796C (en) 2015-11-03
EP2138512B1 (en) 2011-11-23
AU2004303633A1 (en) 2005-07-07
ATE534665T1 (de) 2011-12-15
US20110104164A1 (en) 2011-05-05
US8877491B2 (en) 2014-11-04
US20110105727A1 (en) 2011-05-05
HK1147268A1 (en) 2011-08-05
CN1906212A (zh) 2007-01-31
CN101724070B (zh) 2015-07-08
EP2218737A3 (en) 2011-05-11
AU2012261567A1 (en) 2013-01-10
AU2009245889A1 (en) 2010-01-07
JP2008500274A (ja) 2008-01-10
PT2138512E (pt) 2012-03-05
JP4652341B2 (ja) 2011-03-16
SI2138512T1 (sl) 2012-04-30
US20140316113A1 (en) 2014-10-23
EP2308894A3 (en) 2011-05-11
US20090300780A1 (en) 2009-12-03
US20110105728A1 (en) 2011-05-05
CY1112611T1 (el) 2016-02-10
IL220128A0 (en) 2012-07-31
PL2218737T3 (pl) 2016-09-30
JP2015110601A (ja) 2015-06-18
EP2138512A1 (en) 2009-12-30
PL2138512T3 (pl) 2012-09-28
JP2012126726A (ja) 2012-07-05
ZA200605200B (en) 2009-08-26
DK1709076T3 (da) 2012-08-27
US20110191872A1 (en) 2011-08-04
JP2009291211A (ja) 2009-12-17
EP1709076B1 (en) 2012-05-23
US8296079B2 (en) 2012-10-23
SI2218737T1 (sl) 2016-03-31
DK2138512T3 (da) 2012-02-27
CA2551796A1 (en) 2005-07-07
CN1906212B (zh) 2013-07-17
AU2004303633B2 (en) 2011-12-08
EP2218737B1 (en) 2015-12-02
CA2688944C (en) 2015-04-07
EP2138512B8 (en) 2012-03-14
EP1709076A2 (en) 2006-10-11
ES2559429T3 (es) 2016-02-12
US8246956B2 (en) 2012-08-21
HUE027475T2 (en) 2016-09-28
IL176495A (en) 2014-05-28
EP2218737A2 (en) 2010-08-18
BRPI0418202A (pt) 2007-04-17
US8257710B2 (en) 2012-09-04
CN101724070A (zh) 2010-06-09
AU2012261567B2 (en) 2016-09-08
HK1139697A1 (en) 2010-09-24
AU2009245889B2 (en) 2012-12-13
AU2016269485A1 (en) 2017-01-05

Similar Documents

Publication Publication Date Title
IL220128A0 (en) Method for the humanization of antibodies and humanized antibodies thereby obtained
TR200200735T2 (tr) CTLA-4 için insan monoklonal antikorları
WO2005016111A3 (en) Antibodies directed to parathyroid hormone (PTH) and uses thereof
IN2009KN02655A (enExample)
DK1827492T3 (da) Antistoffer rettet mod GPNMB og anvendelser deraf
ATE417067T1 (de) Rs7 antikörper
CY1112909T1 (el) Αντισωματα που κατευθυνονται εναντια στην αγγειοποιητινη (angiopoietin)-2 και χρησεις αυτων
WO2006130458A3 (en) Antibodies directed to cd20 and uses thereof
CY1112843T1 (el) Μεθοδος παρασκευης υβριδικων αντισωματων
ATE509955T1 (de) Humanisierte kollagen-antikörper und damit verbundene verfahren
WO2004050683A3 (en) Antibodies directed to tumor necrosis factor and uses thereof
WO2004016769A3 (en) Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
WO2006039258A3 (en) Human antibodies against parathyroid hormone
WO2004050850A3 (en) Antibodies directed to phospholipase a2 and uses thereof
WO2003057857A3 (en) Antibodies directed to pdgfd and uses thereof
WO2005047325A3 (en) Monkey immunoglobulin sequences